The global market for obesity treatments is witnessing a paradigm shift from injectable drugs like Wigovi and Maunza to oral medications, driven by the convenience of oral GLP-1 receptor agonists. This trend raises concerns for market leaders Novo Nordisk and Eli Lilly as new oral treatments, such as Structure Therapeutics’ aleniglipron, show promising results in clinical trials, potentially breaking the existing dual monopoly of these companies. On June 16, Structure Therapeutics announced encouraging Phase 2 results for aleniglipron, where patients taking a 180mg dose achieved an average weight loss of 16.3% compared to a placebo over 44 weeks, with continued weight loss in follow-up studies extending to 56 weeks, outperforming existing oral treatments from leading competitors.

Although Novo Nordisk's oral Wegovy, which recently received FDA approval in January, is a market leader, its strict requirement for ingestion during fasting poses a significant challenge for user compliance. Conversely, both Structure's aleniglipron and Eli Lilly's orforglipron, expected to gain FDA approval by April 10, offer oral formulations that do not impose dietary restrictions, posing a substantial competitive advantage that may threaten Novo Nordisk’s leading position. As these pharmaceutical companies navigate this evolving landscape, one of the primary obstacles for oral GLP-1 therapies remains the management of gastrointestinal side effects, a concern highlighted by past safety issues related to potential liver toxicity in previous drug developments like Pfizer's danuglipron, which was discontinued due to safety complications.